Effect ofSLCO1B1Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis
2015 ◽
Vol 60
(1)
◽
pp. 617-620
◽
Keyword(s):
ABSTRACTRifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects ofSLCO1B1polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers ofSLCO1B1rs1104581 (previously associated with low rifampin concentrations). Larger studies are needed to understand the complex interactions of host genetics in HIV-infected tuberculosis patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT00640887.)
2021 ◽
2018 ◽
Vol 74
(5)
◽
pp. 583-591
◽
2016 ◽
Vol 16
(12)
◽
pp. 12362-12368
◽
2011 ◽
Vol 91
(2)
◽
pp. 234-242
◽
1996 ◽
Vol 1
(1)
◽
pp. 107
◽
2015 ◽
Vol 25
(3)
◽
pp. 212-218
◽
1996 ◽
Vol 26
(4)
◽
pp. 560-565
◽